Spontaneous Haematomas of Psoas Occurring in Intensive Care

Psoas Hematomas Clinical Trial

Official title:

Spontaneous Haematomas of Psoas Occurring in Intensive Care: Incidence, Patient Characteristics and Treatment, a Retrospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03452631
• Other study ID #: 6838
• Status: Completed
• Start date: October 1, 2017
• Est. completion date: December 31, 2017

Study information

• Verified date: June 2022
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Psoas hematomas are a rare and potentially lethal pathology whose incidence in resuscitation is unknown. The pathophysiology of this pathology is not known to date.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 31, 2017
• Est. primary completion date: December 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major patients

• Psoas hematoma diagnosed during hospitalization

Exclusion Criteria:

• Refusal to participate in the study

Related Conditions & MeSH terms

• Hematoma
• Psoas Hematomas

Locations

Country	Name	City	State
France	Service de Réanimation médicale	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of psoas hematomas		72 hours after admission to intensive care